📰 Solid Tumors News
Page 24 - Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.
October 15, 2023
Novocure today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 ? 24 in Madrid. Novocure will present three new posters on Tumor Treating Fields (TTFields) therapy, including an analysis...
October 11, 2023
TJ-L14B/ABL503 demonstrated preliminary efficacy signals in the form of responses in patients with progressive, locally advanced or metastatic solid tumors who were relapsed or refractory after previous lines of therapy.
October 9, 2023
KURA | Complete Kura Oncology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
September 27, 2023
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel r...
September 27, 2023
ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R mutations in KRASAs of the April 25, 2023 data cut-off date, among the 22 evaluable patients,...
September 26, 2023
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel...
September 22, 2023
Merck , known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus...
September 22, 2023
First Phase 3 results for the KEYTRUDA® and Padcev® combination showed a statistically significant and clinically meaningful improvement in OS, PFS and key secondary endpoint of overall response...
September 21, 2023
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)Sep 19, 2023 6:00 AMRegulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwideTEVIMBRA is the cornerstone of BeiGene...
September 21, 2023
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®Sep 19, 2023 6:15 AMEuropean Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma (ESCC)U.S. FDA accepts Biologics License Ap...